The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece
Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods...
Gespeichert in:
| Veröffentlicht in: | Digestion 2014-01, Vol.90 (4), p.229-231 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 231 |
|---|---|
| container_issue | 4 |
| container_start_page | 229 |
| container_title | Digestion |
| container_volume | 90 |
| creator | Karamanolis, Georgios P. Daikos, George L. Xouris, Dimitrios Goukos, Dimitrios Delladetsima, Ioanna Ladas, Spiros D. |
| description | Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods (in 2000 and in 2010). Methods: Gastric biopsies of consecutive H. pylori-positive patients were investigated retrospectively. Mutations in H. pylori 23S rRNA and gyrA genes associated with resistance to clarithromycin and quinolones, respectively, were determined by allelic specific polymerase chain reaction. Results: In the first time period (2000), H. pylori resistance patterns were evaluated in 50 and in the second period (2010) in 57 patients. During the first time period 30 and 0% of patients were infected with clarithromycin- or quinolone-resistant strains, respectively. In the second time period (2010), the percentage of patients infected with clarythromycin or quinolone resistance strains increased to 42 and 5.3%, respectively. Conclusions: Our study showed an increase in the prevalence of both clarithromycin and quinolones resistance of H. pylori. Although the resistance rate to quinolones increased over the years, it is relatively low justifying its use for the eradication of H. pylori infections. © 2015 S. Karger AG, Basel |
| doi_str_mv | 10.1159/000369898 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000369898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3626406291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-b851494d82270bf1df8121d36db9d975690c08caef3f93da21df92db303605563</originalsourceid><addsrcrecordid>eNqF0c1LwzAYBvAgis7pwbtIwIseqvlo2uQ4xvyAwcSPg6eSpm812jWatIP992Zs7uDFUwj55YH3fRA6oeSKUqGuCSE8U1LJHTSgKaOJklm-iwaEUJYwyfgBOgzhY3VVKd9HB0wITpXgA_T0_A54snBN31nXYlfjO2iscaU2HXj8sGyct3jUdra0rrMm4EcINnS6NYBni0gowa-gfcC2xbcewMAR2qt1E-B4cw7Ry83keXyXTGe39-PRNDE8y7uklIKmKq0kYzkpa1rVkjJa8awqVaVykSliiDQaal4rXun4VitWlTwOS4TI-BBdrHO_vPvuIXTF3AYDTaNbcH0oaC4F4yxn_H-axYVwwtJV6vkf-uF638ZBosq4SlMRlzhEl2tlvAvBQ118eTvXfllQUqxKKbalRHu2SezLOVRb-dtCBKdr8Kn9G_gt2Pz_Af0BjL0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1663944594</pqid></control><display><type>article</type><title>The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece</title><source>MEDLINE</source><source>Karger Journals</source><creator>Karamanolis, Georgios P. ; Daikos, George L. ; Xouris, Dimitrios ; Goukos, Dimitrios ; Delladetsima, Ioanna ; Ladas, Spiros D.</creator><creatorcontrib>Karamanolis, Georgios P. ; Daikos, George L. ; Xouris, Dimitrios ; Goukos, Dimitrios ; Delladetsima, Ioanna ; Ladas, Spiros D.</creatorcontrib><description>Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods (in 2000 and in 2010). Methods: Gastric biopsies of consecutive H. pylori-positive patients were investigated retrospectively. Mutations in H. pylori 23S rRNA and gyrA genes associated with resistance to clarithromycin and quinolones, respectively, were determined by allelic specific polymerase chain reaction. Results: In the first time period (2000), H. pylori resistance patterns were evaluated in 50 and in the second period (2010) in 57 patients. During the first time period 30 and 0% of patients were infected with clarithromycin- or quinolone-resistant strains, respectively. In the second time period (2010), the percentage of patients infected with clarythromycin or quinolone resistance strains increased to 42 and 5.3%, respectively. Conclusions: Our study showed an increase in the prevalence of both clarithromycin and quinolones resistance of H. pylori. Although the resistance rate to quinolones increased over the years, it is relatively low justifying its use for the eradication of H. pylori infections. © 2015 S. Karger AG, Basel</description><identifier>ISSN: 0012-2823</identifier><identifier>EISSN: 1421-9867</identifier><identifier>DOI: 10.1159/000369898</identifier><identifier>PMID: 25531953</identifier><identifier>CODEN: DIGEBW</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Clarithromycin ; DNA Gyrase - genetics ; Drug Resistance, Bacterial - genetics ; Gene Frequency ; Greece - epidemiology ; Helicobacter Infections - epidemiology ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Helicobacter pylori - genetics ; Humans ; Levofloxacin ; Molecular Epidemiology ; Mutation ; Polymorphism, Single Nucleotide ; Prevalence ; Retrospective Studies ; RNA, Ribosomal, 23S - genetics ; Short Communication</subject><ispartof>Digestion, 2014-01, Vol.90 (4), p.229-231</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>2015 S. Karger AG, Basel.</rights><rights>Copyright (c) 2015 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-b851494d82270bf1df8121d36db9d975690c08caef3f93da21df92db303605563</citedby><cites>FETCH-LOGICAL-c367t-b851494d82270bf1df8121d36db9d975690c08caef3f93da21df92db303605563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25531953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karamanolis, Georgios P.</creatorcontrib><creatorcontrib>Daikos, George L.</creatorcontrib><creatorcontrib>Xouris, Dimitrios</creatorcontrib><creatorcontrib>Goukos, Dimitrios</creatorcontrib><creatorcontrib>Delladetsima, Ioanna</creatorcontrib><creatorcontrib>Ladas, Spiros D.</creatorcontrib><title>The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece</title><title>Digestion</title><addtitle>Digestion</addtitle><description>Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods (in 2000 and in 2010). Methods: Gastric biopsies of consecutive H. pylori-positive patients were investigated retrospectively. Mutations in H. pylori 23S rRNA and gyrA genes associated with resistance to clarithromycin and quinolones, respectively, were determined by allelic specific polymerase chain reaction. Results: In the first time period (2000), H. pylori resistance patterns were evaluated in 50 and in the second period (2010) in 57 patients. During the first time period 30 and 0% of patients were infected with clarithromycin- or quinolone-resistant strains, respectively. In the second time period (2010), the percentage of patients infected with clarythromycin or quinolone resistance strains increased to 42 and 5.3%, respectively. Conclusions: Our study showed an increase in the prevalence of both clarithromycin and quinolones resistance of H. pylori. Although the resistance rate to quinolones increased over the years, it is relatively low justifying its use for the eradication of H. pylori infections. © 2015 S. Karger AG, Basel</description><subject>Clarithromycin</subject><subject>DNA Gyrase - genetics</subject><subject>Drug Resistance, Bacterial - genetics</subject><subject>Gene Frequency</subject><subject>Greece - epidemiology</subject><subject>Helicobacter Infections - epidemiology</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - genetics</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Molecular Epidemiology</subject><subject>Mutation</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prevalence</subject><subject>Retrospective Studies</subject><subject>RNA, Ribosomal, 23S - genetics</subject><subject>Short Communication</subject><issn>0012-2823</issn><issn>1421-9867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqF0c1LwzAYBvAgis7pwbtIwIseqvlo2uQ4xvyAwcSPg6eSpm812jWatIP992Zs7uDFUwj55YH3fRA6oeSKUqGuCSE8U1LJHTSgKaOJklm-iwaEUJYwyfgBOgzhY3VVKd9HB0wITpXgA_T0_A54snBN31nXYlfjO2iscaU2HXj8sGyct3jUdra0rrMm4EcINnS6NYBni0gowa-gfcC2xbcewMAR2qt1E-B4cw7Ry83keXyXTGe39-PRNDE8y7uklIKmKq0kYzkpa1rVkjJa8awqVaVykSliiDQaal4rXun4VitWlTwOS4TI-BBdrHO_vPvuIXTF3AYDTaNbcH0oaC4F4yxn_H-axYVwwtJV6vkf-uF638ZBosq4SlMRlzhEl2tlvAvBQ118eTvXfllQUqxKKbalRHu2SezLOVRb-dtCBKdr8Kn9G_gt2Pz_Af0BjL0</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Karamanolis, Georgios P.</creator><creator>Daikos, George L.</creator><creator>Xouris, Dimitrios</creator><creator>Goukos, Dimitrios</creator><creator>Delladetsima, Ioanna</creator><creator>Ladas, Spiros D.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20140101</creationdate><title>The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece</title><author>Karamanolis, Georgios P. ; Daikos, George L. ; Xouris, Dimitrios ; Goukos, Dimitrios ; Delladetsima, Ioanna ; Ladas, Spiros D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-b851494d82270bf1df8121d36db9d975690c08caef3f93da21df92db303605563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Clarithromycin</topic><topic>DNA Gyrase - genetics</topic><topic>Drug Resistance, Bacterial - genetics</topic><topic>Gene Frequency</topic><topic>Greece - epidemiology</topic><topic>Helicobacter Infections - epidemiology</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - genetics</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Molecular Epidemiology</topic><topic>Mutation</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prevalence</topic><topic>Retrospective Studies</topic><topic>RNA, Ribosomal, 23S - genetics</topic><topic>Short Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karamanolis, Georgios P.</creatorcontrib><creatorcontrib>Daikos, George L.</creatorcontrib><creatorcontrib>Xouris, Dimitrios</creatorcontrib><creatorcontrib>Goukos, Dimitrios</creatorcontrib><creatorcontrib>Delladetsima, Ioanna</creatorcontrib><creatorcontrib>Ladas, Spiros D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Digestion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karamanolis, Georgios P.</au><au>Daikos, George L.</au><au>Xouris, Dimitrios</au><au>Goukos, Dimitrios</au><au>Delladetsima, Ioanna</au><au>Ladas, Spiros D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece</atitle><jtitle>Digestion</jtitle><addtitle>Digestion</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>90</volume><issue>4</issue><spage>229</spage><epage>231</epage><pages>229-231</pages><issn>0012-2823</issn><eissn>1421-9867</eissn><coden>DIGEBW</coden><abstract>Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods (in 2000 and in 2010). Methods: Gastric biopsies of consecutive H. pylori-positive patients were investigated retrospectively. Mutations in H. pylori 23S rRNA and gyrA genes associated with resistance to clarithromycin and quinolones, respectively, were determined by allelic specific polymerase chain reaction. Results: In the first time period (2000), H. pylori resistance patterns were evaluated in 50 and in the second period (2010) in 57 patients. During the first time period 30 and 0% of patients were infected with clarithromycin- or quinolone-resistant strains, respectively. In the second time period (2010), the percentage of patients infected with clarythromycin or quinolone resistance strains increased to 42 and 5.3%, respectively. Conclusions: Our study showed an increase in the prevalence of both clarithromycin and quinolones resistance of H. pylori. Although the resistance rate to quinolones increased over the years, it is relatively low justifying its use for the eradication of H. pylori infections. © 2015 S. Karger AG, Basel</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>25531953</pmid><doi>10.1159/000369898</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-2823 |
| ispartof | Digestion, 2014-01, Vol.90 (4), p.229-231 |
| issn | 0012-2823 1421-9867 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000369898 |
| source | MEDLINE; Karger Journals |
| subjects | Clarithromycin DNA Gyrase - genetics Drug Resistance, Bacterial - genetics Gene Frequency Greece - epidemiology Helicobacter Infections - epidemiology Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - genetics Humans Levofloxacin Molecular Epidemiology Mutation Polymorphism, Single Nucleotide Prevalence Retrospective Studies RNA, Ribosomal, 23S - genetics Short Communication |
| title | The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in Greece |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A18%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evolution%20of%20Helicobacter%20Pylori%20Antibiotics%20Resistance%20Over%2010%20Years%20in%20Greece&rft.jtitle=Digestion&rft.au=Karamanolis,%20Georgios%20P.&rft.date=2014-01-01&rft.volume=90&rft.issue=4&rft.spage=229&rft.epage=231&rft.pages=229-231&rft.issn=0012-2823&rft.eissn=1421-9867&rft.coden=DIGEBW&rft_id=info:doi/10.1159/000369898&rft_dat=%3Cproquest_cross%3E3626406291%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1663944594&rft_id=info:pmid/25531953&rfr_iscdi=true |